Anavex Life Sciences Corp (AVXL)

[tschussmann1]

I cannot argue the impact of the small sample size for the control in Rett; it likely was the reason for lack of statistical significance. The non-stat significant metric for Alzheimer's possibly would have still failed with a larger sample size, as it has been postulated not to be a good measure of effectiveness for early Alzheimer's treatments. Perhaps the only reason for inclusion was the FDA requirements of the time.
What I expect to result in a favorable outcome for me is that I was able to acquire the majority of my position post Rett data reveal. Need one of: EMA approval for A 2-73, or demonstrated effectiveness for A 3-71 on Schizophrenia. I believe the odds are in our favor.